Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Sangamo Biosciences (SGMO) Stock Price & Analysis
1,568 Followers
SGMO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.29 - $1.67
Previous Close$0.65
Volume1.95M
Average Volume (3M)2.03M
Market Cap
$134.80M
Enterprise Value$87.31M
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$33.52M
Price to Earnings (P/E)-0.3
Beta1.34
Next Earnings
Aug 07, 2024EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding207,510,076
10 Day Avg. Volume2,682,262
30 Day Avg. Volume2,029,942
Standard Deviation0.28
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.63
Price to Sales (P/S)0.77
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$2.60Price Target Upside323.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Sangamo Biosciences News
PremiumCompany Announcements
Sangamo Biosciences: Navigating Biopharma Risks Beyond the Minefield
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Regulatory AdvancementsAlignment with U.S. and EU regulators may enable a faster pathway to regulatory submissions.
Product Pipeline DevelopmentThe unveiling of the MINT platform designed to enable the insertion of large DNA sequences could unlock a broader neurology genetic medicine pipeline.
Strategic PartnershipsSangamo's strategy to secure a collaboration partner could provide a potential source of non-dilutive funding.
Bears Say
Capital Markets And DilutionRisks include capital markets and dilution, which could impact shareholder value if the company seeks additional funding through equity offerings.
Clinical DevelopmentSangamo is stopping further development of its clinical programs in Fabry disease and CAR-Treg cell therapy, indicating a potential setback in the company's product pipeline.
Financial PerformanceSGMO reported a net loss per share of ($0.34), which was higher than the consensus estimate of ($0.26), reflecting financial results that were below market expectations.
---
Ownership Overview
16.53% Insiders
24.17% Mutual Funds
26.88% Other Institutional Investors
32.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.29 and its highest was $1.67 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Currently, no data Available
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Aug 07, 2024 which is in 78 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on May 09, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.056.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -$0.14.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 207,510,070 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Among the largest hedge funds holding Sangamo Biosciences’s share is Wexford Capital LP. It holds Sangamo Biosciences’s shares valued at N/A.
---
Sangamo Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.60 (323.04% Upside)
$2.60 (323.04% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 45.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.92%
12-Months-Change
Fundamentals
Return on Equity
-167.24%
Trailing 12-Months
Asset Growth
-70.73%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
---
SGMO Company Deck
---
SGMO Earnings Call
Q1 2024
0:00 / 0:00
---
SGMO Stock 12 Month Forecast
Average Price Target
$2.60
▲(323.04% Upside)
Technical Analysis
Best Analysts Covering SGMO
1 Year
---